EUVIMEDEUVIMED entdecken
Crossref

Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types

Xiujie Yang, Qi Yin, Kui Li, Jianze Wang, Rui Song, Haoyi Zhou, Shu Han, Linyu Zhang, Yuwen Zeng, Da Xu, Feng Wang, Shixin Zhou und 7 weitere

Cell Stem Cell · 2026

DOI: 10.1016/j.stem.2026.07.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Stem Cell, 2026. Verfasst von Xiujie Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Department of Nuclear Medicine, Peking University Third Hospit…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Radiopharmaceuticals, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Peking University, Natural Science Foundation of Beijing Municipality, Michigan Medicine-PKUHSC Joint Institute for Translational and Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceutical-based imaging and targeted radionuclide therapy are often limited by heterogeneous or absent molecular targets in tumors. Here, we present a stiffness-responsive mesenchymal stem cell (MSC)-assisted relayed tumor-targeting (SMART) platform that converts matrix stiffness into a programmable molecular entry point for radiotheranostics. Engineered MSCs sense elevated mechanical stiffness within the tumor microenvironment and induce localized expression of synthetic biomarkers, thereby enabling radiopharmaceutical targeting independent of endogenous target availability. As a proof of concept, SMART-driven expression of prostate-specific membrane antigen (PSMA) enables sensitive tumor detection by 68Ga-PSMA-617 positron emission tomography (PET) and effective treatment with 177Lu-AB-PSMA-617 across multiple tumor models, with improved sensitivity and reduced off-target uptake compared with conventional 18F-fluorodeoxyglucose PET. This platform is readily adaptable to alternative synthetic targets and induced pluripotent stem cell (iPSC)-derived MSCs. By translating a universal physical feature of tumors into an actionable molecular signature, SMART expands the scope of precision radiotheranostics beyond native biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsRadiopharmaceuticalsNeoplasmsHumansAnimalsPositron-Emission TomographyAntigens, SurfaceCell Line, TumorMaleMiceTumor Microenvironment

Stichwörter der Autor:innen

positron emission tomographyprostate-specific membrane antigenradionuclide therapytheranosticstumor stiffness

Substanzen

RadiopharmaceuticalsAntigens, Surface

Autor:innen und Institutionen

  • Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Department of Nuclear Medicine, Peking University Third Hospital, Beijing 100191, China.
  • Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, Department of Nuclear Medicine, Peking University Third Hospital, Beijing 100191, China; Key Laboratory of Carcinogenesis and Transl…
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nucl…
  • Department of Cell Biology, School of Basic Medical Sciences, Peking University Stem Cell Research Center, Peking University, Beijing 100191, China.
  • Breast Center, Peking University Cancer Hospital and Institute, Beijing 100142, China.
  • Frontiers Science Center for Cancer Integrative Omics, Peking University International Cancer Institute, Peking University, Beijing 100191, China.

Förderung

  • Peking University
  • Natural Science Foundation of Beijing Municipality
  • Michigan Medicine-PKUHSC Joint Institute for Translational and Clinical Research
  • National Major Science and Technology Projects of China
  • National Science and Technology Major Project
  • National Natural Science Foundation of China

Zitieren

APA

Yang, X., Yin, Q., Li, K., Wang, J., Song, R., Zhou, H., Han, S., Zhang, L., Zeng, Y., Xu, D., Wang, F., Zhou, S., Yang, Y., Zhu, H., Zheng, C., Li, Y., Yang, Z., Yang, X., & Liu, Z. (2026). Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types. Cell Stem Cell. https://doi.org/10.1016/j.stem.2026.07.015

Vancouver

Yang X, Yin Q, Li K, Wang J, Song R, Zhou H, et al. Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types. Cell Stem Cell. 2026. doi:10.1016/j.stem.2026.07.015

BibTeX
@article{Yang2026,
  author = {Yang, Xiujie and Yin, Qi and Li, Kui and Wang, Jianze and Song, Rui and Zhou, Haoyi and Han, Shu and Zhang, Linyu and Zeng, Yuwen and Xu, Da and Wang, Feng and Zhou, Shixin and Yang, Yang and Zhu, Hua and Zheng, Chunhong and Li, Yang and Yang, Zhi and Yang, Xing and Liu, Zhaofei},
  title = {Engineered mechanosensitive MSCs enable synthetic radiotheranostic targeting across tumor types},
  journal = {Cell Stem Cell},
  year = {2026},
  doi = {10.1016/j.stem.2026.07.015}
}
Kostenlos starten →